A Comprehensive Review on Solid Lipid Nanoparticles as Delivery Vehicle for Enhanced Pharmacokinetic and Pharmacodynamic Activity of Poorly Soluble Drugs

DOI:

https://doi.org/10.37285/ijpsn.2019.12.2.1

Authors

  • Narendar Dudhipala

Abstract

This article describes the current state and future perspectives of solid lipid nanoparticles for achieving high delivery of drugs with greater therapeutic outcomes.  The oral route is the most preferred route of administration for majority of drugs. Problems such as poor solubility or chemical stability in the environment of the gastrointestinal tract, poor permeability through the biological membranes or sensitivity to metabolism are well known to result in the rejection of potential drug candidates as oral delivery products. Hence, lipid-based drug delivery systems have been proposed as a means of bypassing the resistant chemical or physical barriers associated with poorly absorbed drugs. Solid lipid nanoparticles (SLNs) can be an attractive one option for oral drug delivery vehicles as they hold tremendous potential to improve the oral bioavailability of drugs, concomitant reduction of drug toxicity and stability of drug in both GIT and plasma. SLNs are in submicron size range and are made of biocompatible and biodegradable materials capable of incorporating both lipophilic and hydrophilic drugs. SLNs are considered as substitute to other colloidal drug systems and are being used as controlled and targeted delivery systems. The SNL technology has greatly revolutionized the delivery systems for poorly soluble drugs. This article describes the methodologies used for preparation and characterization of SNLs.  It outlined the development of stable solid lipid nanoparticles by different techniques. Further, it describes the current status of pharmacokinetic and pharmaco-dynamic studies reported on SLN systems. Finally, it provides a brief outlook on current marketed preparation and the future scope of SLN technology.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Downloads

Published

2019-03-31

How to Cite

1.
Dudhipala N. A Comprehensive Review on Solid Lipid Nanoparticles as Delivery Vehicle for Enhanced Pharmacokinetic and Pharmacodynamic Activity of Poorly Soluble Drugs. Scopus Indexed [Internet]. 2019 Mar. 31 [cited 2024 Jul. 15];12(2):4421-40. Available from: https://www.ijpsnonline.com/index.php/ijpsn/article/view/289

Issue

Section

Review Articles

References

Aji Alex MR, Chacko AJ, Jose S and Souto EB. (2011). Lopinavir loaded solid lipid nanoparticles (SLN) for intestinal lymphatic targeting. Euro J Pharm Sci 42: 11-18.
Allen DD, Lockman PR, Oyewumi MO, Koziara JM, Roder KE and Mumper RJ. (2003). Brain uptake of thiamine-coated nanoparticles. J Control Rel 93(3): 271-282.
Almeida AJ, Runge S and Muller RH. (1997). Peptide-loaded solid lipid nanoparticles (SLN): influence of production parameters. Int J Pharm 149: 255-65.
Anand KK, Parameswara Rao V, Priyanka K, Sanjay Kumar S and Sanjay S. (2013). Development and Evaluation of Solid Lipid Nanoparticles of Raloxifene Hydrochloride for Enhanced Bioavailability. BioMed Res Int 1- 9.
Andrew J. Humberstone and William N. Charman. (1997). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev 25: 103-128.
Arjun N and Kishan V. (2013). Preparation, characterization and evaluation of quetiapine fumarate solid lipid nanoparticles to improve the oral bioavailability. J Pharmc 1-7.
Arun BR and Narendar D. (2017). Development of multiple-unit floating drug delivery system of clarithromycin: formulation, in vitro dissolution by modified dissolution apparatus, in vivo radiographic studies in human volunteers. Drug res 67: 412-418.
Arun Butreddy, Narendar Dudhipala and Kishan Veerabrahma. (2018). Development of olmesartan medoxomil lipid based nanoparticles and nanosuspension: Preparation, characteri-zation and comparative pharmacokinetic evaluation. Artificial cells, nanomed biotech 46(1): 126-137.
Bargoni A, Cavalli R, Caputo O, et al. (1998). Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. Pharm Res 15: 745-50.
Butreddy A and Dudhipala N. (2015). Enhancement of solubility and dissolution rate of trandolapril sustained release matrix tablets by liquisolid compact approach. Asian J Pharm 9(4): 290-297.
Castelli F, Puglia C, Sarpietro MG, et al. (2005). Characterization of indomethacin-loaded lipid nanoparticles by differential scanning calorimetry. Int J Pharm 304: 231-38.
Catherine Charcosset, Assma Ahmed El-Harati and Hatem Fessi. (2006). A membrane contactor for the preparation of solid lipid nanoparticles. Desalination 200: 570-571.
Cavalli R, Bargoni A, Podio V, et al. (2003). Duodenal administration of solid lipid nanoparticles loaded with different percentages of tobramycin. J Pharm Sci 92: 1085-95.
Cavalli R, Caputo O, Carlotti ME, et al. (1997). Sterilization and freeze-drying of drug-free and drug-loaded solid lipid nanoparticles. Int J Pharm 148: 47-54.
Cavalli R, Peira E, Caputo O, et al. (1999). Solid lipid nanoparticles as carriers of hydrocortisone and progesterone complexes with β-cyclodextrins. Int J Pharm 182: 59-69.
Chalikwar SS, Belgamwar VS, Talele VR, Surana SJ and Patil MU. (2012). Formulation and evaluation of Nimodipine-loaded solid lipid nanoparticles delivered via lymphatic transport system. Coll Surf B: Biointerf 97:109-16.
Chinna Reddy P, Narendar D, Sunil Kumar B, Satyanarayana G, and Madhusudan Rao Y. (2015). Combined dosage form of pioglitazone and felodipine as mucoadhesive pellets via hot melt extrusion for improved buccal delivery with application of quality by design approach. J Drug Del Sci Tech 30: 209-219.
Chinna Reddy Palem, Narendar D, Sunil Kumar Battu, Michael A. Repka, and Madhusudan Rao Yamsani. (2015). Development, optimization and in vivo characterization of domperidone controlled release hot melt extruded films for buccal delivery. Drug Dev Ind Pharm 4: 1-12.
Cortesi R, Esposito E, Luca G, et al. (2002). Production of lipospheres as carriers for bioactive compounds. Biomaterials, 23:2283–94.
Damgé C., Michel C., and Aprahamian M. (1990). Nanocapsules as carriers for oral peptide delivery. J Control Rel 13: 233–239.
De Campos A, Sanchez A, and Alonso MJ. (2001). Chitosan nanoparticles: a new vehicle for the improvement of the ocular retention of drugs. Application to cyclosporin A. Int J Pharm 224: 159-68.
De Campos AM, Sanchez A, Gref R, et al. (2003). The effect of a PEG versus a chitosan coating on the interaction of drug colloidal carriers with the ocular mucosa. Eur J Pharm Sc, 20:73–81.
Demirel M, Yazan Y, Muller RH, et al. (2001). Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul 18: 359-71.
Diederichs JE, and Müller RH. (1994). Liposomes in cosmetics and pharmaceutical products. Pharm Ind 56 (3): 267-275.
Dingler A, Blum RP, Niehus H, et al. (1999). Solid lipid nanoparticles (SLN™/Lipopearls™) – a pharmaceutical and cosmetic carrier for the application of vitamin E in dermal products. J Microencapsul 16: 751-67.
Dudhipala N, and Veerabrahma K. (2017). Improved anti-hyperlipidemic activity of Rosuvastatin Calcium via lipid nanoparticles: pharmacokinetic and pharmacodynamic evaluation. Euro J Pharm Biopharm 110 (1): 47-57.
Dudhipala N. (2017). Ocular iontophoresis for anterior and posterior segment drug delivery. Saudi J Med Pharm Sci 3(8A):853-857.
Florence AT, Hillery AM, Hussain N, et al. (1995). Nanoparticles as carriers for oral peptide absorption: Studies on particle uptake and fate. J Control Rel 36:39-46.
Florence AT. (1997). The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259-66.
Freitas C, and Müller RH. (1998). Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticles (SLN) dispersions. Int J Pharm 168; 221-229.
Freitas C, Muller RH. (1998). Spray-drying of solid lipid nanoparticles (SLNTM). Eur J Pharm Biopharm 46: 145-51.
Fundaro A, Cavalli R, Bargoni A, et al. (2000). Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after iv administration to rats. Pharm Res 42: 337-43.
Garcia-Garcia E, Andrieux K, Gil S, et al. (2005). A methodology to study intracellular distribution of nanoparticles in brain endothelial cells. Int J Pharm 298: 310–4.
Gasco MR. (1993). Method for producing solid lipid microspheres having a narrow size distribution. United States Patent US 188837.
Gohla SH, and Dingler A. (2001). Scaling up feasibility of the production of solid lipid nanoparticles (SLN™). Pharmazie 56: 61-3.
Goppert TM, and Muller RH. (2005). Adsorption kinetics of plasma proteins on solid lipid nanoparticles for drug targeting. Int J Pharm 302: 172–86.
Graham CW, Pagano RR, Katz RL. (1977). Thrombophlebitis after intravenous diazepam - can it be prevented. Anesth Analg 56: 409-413.
Hanafy A, Spahn-Langguth H, Vergnault G, et al. (2007). Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug. Adv Drug Deliv Rev 59: 419-26.
Hao J, Wang F, Wang X, et al. (2012). Development and optimization of baicalin-loaded solid lipid nanoparticles prepared by coacervation method using central composite design. Eu J Phar Sci 47: 497-505.
Harshad H, Manasmita D, and Sanyog J. (2011). Solid lipid nanoparticles: an oral bioavailability enhancer vehicle. Expert Opin Drug Deliv 8(11): 1407-24.
Heiati H, Tawashi R, and Phillips NC. (1998). Solid lipid nanoparticles as drug carriers: plasma stability and biodistribution of solid lipid nanoparticles containing the lipophilic prodrug 3'-azido-3'-deoxythymidine palmitate in mice. Int J Pharm 174: 71-80.
Ho Lun Wong, Reina Bendayan, Andrew M. Rauth, Yongqiang Li, and Xiao Yu W. (2007). Chemotherapy with anticancer drugs encapsulated in solid lipid nanoparticles Adv Drug Deliv Rev 59: 491-504.
Hou DZ, Xie CS, Huang K, et al. (2003). The production and characteristics of solid lipid nanoparticles (SLNs). Biomaterials 24:1781–85.
HouLi Li, XiaoBin Zhao, YuKun Ma, GuangXi Zhai, LingBing Li, Hong Xiang Lou. (2009). Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles J Control Rel 133(10): 238-244.
Hu FQ, Hong Y, and Yuan H. (2004). Preparation and characterization of solid lipid nanoparticles containing peptide. Int J Pharm 273(1–2): 29-35.
Hu FQ, Jiang SP, Du YZ, et al. (2005). Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Coll Surf B: Biointerf 45: 167-73.
Hu LD, Xing Q, Meng J, et al. (2010). Preparation and enhanced oral bioavailability of cryptotanshinone-loaded solid lipid nanoparticles. AAPS PharmSciTech 11:1-6.
Igartua M, Saulnier P, Heurtault B, et al. (2002). Development and characterization of solid lipid nanoparticles loaded with magnetite. Int J Pharm 233: 149-57.
Jani PU, Halbert GW, Langridge J, et al. (1990). Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J Pharm Pharmacol 42: 821-6.
Jenning V, Gysler A, Schafer-Korting M, et al. (2000a). Vitamin A-loaded solid lipid nanoparticles for topical use: occlusive properties and drug targeting to the upper skin. Eur J Pharm Biopharm 49: 211-8.
Jenning V, Scha¨fer-Korting M, and Gohla S. (2000). Vitamin A-loaded solid lipid nanoparticles for topical use: drug release properties, J Control Rel 66: 115-126.
Jores K, Mehnert W, Dreschler M, et al. (2004). Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, fi eld-flow fractionation and transmission electron microscopy. J Control Rel 95: 217-7.
Kakizawa Y, and Kataoka K. (2002). Block copolymer micelles for delivery of gene and related compounds. Adv Drug Deliv Rev 54: 203-2.
Kreuter J. (1991). Peroral administration of nanoparticles. Adv Drug Deliv Rev 7: 71-86.
Kreuter J. (2001). Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 47: 65-81.
Lander R, Manger W, Scouloudis M, et al. (2000). Gaulin homogenization: a mechanistic study. Biotech- nol Prog 16: 80-85.
Liedtke S, Wissing SA, Muller RH, et al. (2000). Inflence of high pressure homogenisation equipment on nanodispersions characteristics. Int J Pharm 196: 183-5.
Liu S. (2008). Solid lipid nanopartiles for pulmonary delivery of insulin. Int J Pharm 356: 333-344.
Luo CF, Yuan M, Chen MS, et al. (2011). Pharmacokinetics, tissue distribution and relative bioavailability of puerarin solid lipid nanoparticles following oral administration. Int J Pharm 410: 138-44.
Luo Y, Chen D, Ren L, et al. (2006). Solid lipid nanoparticles for enhancing vinpocetine’s oral bioavailability. J Control Rel 114: 53-9.
Manjunath K, and Venkateswarlu V. (2006). Pharmacokinetics, tissue distribution and bioavailability of nitrendipine solid lipid nanoparticles after intravenous and intraduodenal administration. J Drug Target 14: 632-45.
Manjunath, K., and Venkateswarlu, V. (2005). Pharmacokinetics, tissue distribution and bioavailability of clozapine solid lipid nanoparticles after intravenous and intraduodenal administration. J Control Rel 107: 215-228.
Mehnert W, and Mäder K. (2001). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev 47: 165-196.
Mehnert W, and Mäder K. (2012). Solid lipid nanoparticles production, characterization and applications. Adv Drug Deliv Rev. 64: 83-101.
Mei Z, Chen H, Weng T, et al. (2003). Solid lipid nanoparticle and microemulsion for topical delivery of triptolide. Eur J Pharm Biopharm 56: 189-96.
Mei Z, Li X, Wu Q, et al. (2005). The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle. Pharm Res 51: 345-51.
Mohammad MM, Saeid D, Soliman MS, and Arman Z. (2013). A novel method to produce solid lipid nanoparticles using n-butanol as an additional co-surfactant according to the o/w microemulsion quenching technique. Chem Physi Lipids 174: 32-38.
Morel S, Terreno E, Ugazio E, et al. (1998). NMR relaxometric investigations of solid lipid nanoparticles (SLN) containing gadolinium (III) complexes. Eur J Pharm Biopharm 45: 157-63.
Mühlen AZ, Schwarz C, and Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled release drug delivery-drug release and release mechanism. Eur J Pharm Biopharm 45: 149-155.
Müller RH, and Keck CM. (2004). Challenges and solutions for the delivery of biotech drugs – a review of drug nanocrystal technology and lipid nanoparticles. J Biotech 113:151-70.
Müller RH, Maaûen, S Weyhers H, et al. (1996). Cytotoxicity of magnetite loaded polylactide, polylactide/glycolide particles and solid lipid nanoparticles (SLN). Int J Pharm 138: 85- 94.
Müller RH, Mehnert W, Lucks JS, et al. (1995). Solid lipid nanoparticles (SLN) – An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41:62–9.
Müller RH, Mehnert W, Lucks JS, Schwarz C, Zur Mühlen A, Weyhers H, Freitas C, and Ruhl D. (1995) Solid lipid nanoparticles (SLN)—An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41: 62–69.
Müller RH, Radtke M, and Wissing SA. (2002a). Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv Drug Deliv Rev 54(1):S131-55.
Müller RH, Runge S, Ravelli V, et al. (2006). Oral bioavailability of cyclosporine: Solid lipid nanoparticles (SLN) versus drug nanocrystals. Int J Pharm 317: 82-9.
Müller RH, Runge SA, Ravelli V, et al. (2008). Cyclosporine-loaded solid lipid nanoparticles (SLN): Drug-lipid physicochemical interactions and characterization of drug incorporation. Eur J Pharm Biopharm 68: 535-44.
Müller RH, and Runge SA. (1998). Solid lipid nanoparticles (SLNR) for controlled drug delivery. In: Benita S edited. Submicron emulsion in drug targeting and delivery. The Netherlands: Harwood Academic Publishers. P 219-34.
Müller RH, Schwarz C, Zur Muhlen A, et al. (1994). Incorporation of lipophilic drugs and drug release profiles of solid lipid nanoparticles (SLN). Proc Int Symp Control Rel Bioact Mate0, 21: 146-7.
Müller, R.H., Mäder, K., and Gohla, S. (2000). Solid lipid nanoparticles (SLN) for controlled drug delivery a review of the state of the art. Eur J Pharm Biopharm 50:161-177.
Nagaraj K, Narendar D, and Kishan V. (2017). Development of olmesartan medoxomil optimized nanosuspension using Box-Behnken design to improve oral bioavailability. Drug Dev Ind Phar 43(7):1186-1196.
Narendar D, Arjun N, Karthik Yadav J, and Ramesh Bomma. (2016). Amoxycillin Trihydrate Floating-Bioadhesive Drug Delivery System for Eradication of Helicobacter pylori: Preparation, In Vitro and Ex Vivo Evaluation. J bioequ avail 8(3): 118-124.
Narendar D, Chinna Reddy P, Sunil R, and Madhusudan Rao Y. (2012). Development of floating matrix tablets of Ofloxacin and Ornidazole in combined dosage form: in vitro and in vivo evaluation in healthy human volunteers. Int J Drug Deli 4: 462-469.
Narendar D, and Govardhan K. (2018). Capecitabine lipid nanoparticles for anti-colon cancer activity in 1, 2-dimethylhydrazine induced colon cancer: Preparation, cytotoxic, pharmacokinetic and pathological evaluation. Drug dev Ind pharm 44(10):1572-1582.
Narendar D, Karthik Yadav J, Thirupathi G. (2018). Comparative study of nisoldipine-loaded nanostructured lipid carriers and solid lipid nanoparticles for oral delivery: preparation, characterization, permeation and pharmacokinetic evaluation. Artificial cells, nanomed biotech. Early online, doi.org/10.1080/21691401.2018.1465068.
Narendar D, and Karthik yadav J. (2017). Lipid nanoparticles of zaleplon for improved oral delivery by Box-Behnken design: Optimization, in vitro and in vivo evaluation.Drug Dev Ind Pharm 43(7):1205-1214.
Narendar D, and Kishan V. (2016). Candesartan cilexetil loaded solid lipid nanoparticles for oral delivery: characterization, pharmacokinetic and pharmacodynamic evaluation. Drug Deliv 23(2):395-4-4.
Narendar D, and Kishan V. (2017). Candesartan cilexetil nanoparticles for improved oral bioavailability. Ther deli 8(2):79-88.
Narendar D, Palem CR, Reddy S, and Rao YM. (2011). Pharmaceutical development and clinical pharmacokinetic evaluation of gastro retentive floating matrix tablets of levofloxacin. Int J Pharm Sci Nanotech 4(3): 1461-1467.
Narendar D. (2017). Polymeric matrices at micro and nanoscale for ocular drug delivery. Saudi J Biomed Res 2(1): 96-100.
Narendar Dudhipala, and Kishan Veerabrahma. (2015). Pharmacokinetic and pharmacodynamic studies of nisoldipine loaded solid lipid nanoparticles by central composite design. Drug Dev Ind Pharm 41(12):1968-1977.
O’Hagan DT. (1990). Intestinal translocation of particulates-implications for drug and antigen delivery. Adv Drug Deliv Rev 5:265-85.
Olbrich C, Bakowski U, Lehr CM, et al. (2001). Cationic solid-lipid nanoparticles can effi ciently bind and transfect plasmid DNA. J Control Rel 77:345–55.
Palem CR, Narendar D, Satyanarayana G, and Varsha B Pokharkar. (2016). Development and optimization of Atorvastatin calcium-cyclodextrin inclusion complexed oral disintegrating tablets for enhancement of solubility, dissolution, pharmacokinetic and pharmacodynamic activity by central composite design. Int J Pharm Sci Nanotech 9(2): 1-11.
Palem CR, Ramesh G, Narender D, Vamshi Vishnu I, and Madhusudan Rao Y. (2011). Transmucosal delivery of domperidone from bilayered buccal patches: in vitro, ex vivo and in vivo characterization. Arch Pharm Res 34(10):1701-1710.
Paliwal R, Rai S, Vaidya B, et al. (2009). Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine: NBM 5:184-91.
Pandey R, Sharma S, and Khuller GK. (2005). Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis 85:415-20.
Pankaj Dwivedi, Renuka Khatik, Kiran Khandelwal, Ishan Taneja, et al. (2014). Pharmacokinetics study of arteether loaded solid lipid nanoparticles: An improved oral bioavailability in rats. Int J Pharm 466:321–327.
Pitta Sravan, Dudhipala Narendar, Narala Arjun, and Veerabrahma Kishan. (2018). Development and evaluation of zolmitriptan transfersomes by Box-Behnken design for improved bioavailability by nasal delivery. Drug Dev Ind Pharm 44(3):484-492.
Ponchel G, Montisci MJ, Dembri A, et al. (1997). Mucoadhesion of colloidal particulate systems in the gastro-intestinal tract. Eur J Pharm Biopharm 44:25–31.
Powers M. (2005). Innovata emerges as first suitor in acquisition play for Skye Pharma. Nanobiotech News 3(45):1.
Quintanar-Guerrero D, Tamayo-Esquivel D, Ganem-Quintanar A, et al. (2005). Adaptation and optimization of the emulsifi cation-diffusion technique to prepare lipidic nanospheres. Eur J Pharm Sci 26:211–8.
Rabea P, FAhmad FJ, Iqbal Z, Samim M, and Sayeed A. (2014). Solid lipid nanoparticles of anticancer drug andrographolide: formulation, in vitro and in vivo studies. Drug dev Ind pharm 40(9): 1206-1212.
Radheshyam Tiwari, and Kamla Pathak. (2011). Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: Comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int J Pharm 415(1-2): 232–243.
Radtke M, and Müller RH. (2011). Novel concept of topical cyclosporine delivery with supersaturated SLNTM creams. Proc. Int. Symp Control Release Bioact Mater.
Ranga Reddy. K, Narendar Reddy. D, Shirisha B and Govardhan P. (2015). Development, characterization and in vivo performance of saquinavir loaded lipid microspheres. Adv Sci Engineer Med 7: 1-8.
Rao KK. (2007). Polymerized solid lipid nanoparticles for oral or mucosal delivery of therapeutic proteins and peptides. PCTIB 2007000896.
Reddy ND, Arjun N, Dinesh S, and Karthik J. (2016). Biopharmaceutical and Preclinical Studies of Efficient Oral Delivery of Zaleplon as Semisolid Dispersions with Self-emulsifying Lipid Surfactants. Int J Pharm Sci Nanotech 9(1):1-8.
Reddy ND, Someshwar K, Arjun N, and Y. Madhusudan Rao. (2016). Quality by design approach for development and optimization of Quetiapine Fumarate effervescent floating matrix tablets for improved oral delivery. J Pharm Investig 46(3): 253-263.
Rohit B, and Indu Pal K. (2013). Pharmacokinetics, tissue distribution and relative bioavailability of isoniazid-solid lipid nanoparticles. Int J Pharm 441: 202–212.
Sandeep V, Narendar D, Arjun N, and Kishan V. (2016). Lacidipine loaded solid lipid nanoparticles for oral delivery: Preparation, characterization and in vivo evaluation. Int J Pharm Sci Nanotech 9(6):3524-30.
Sanjula B. (2009). Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 17:249-56.
Sanket N., Palak K., Bharadia P.D, and Modi D.A. (2011). Novel drug delivery system for lipophilic Agents: Solid lipid nanoparticles. IJPI’s J of Pharm Cosmetol 1(4): 77-89.
Scheffel U, Rhodes BA, Natajaran TK, and Wagner Jr HN. (1970). Albumin microspheres for study of the reticuloendothelial system. J Nucl Med 13: 498–503.
Schubert MA, Harms M, and Muller-Goyman CC. (2006). Sructural investigations on lipid nanoparticles containing high amounts of lecithin. Eur J Pharm Sci 27:226–36.
Schubert MA, and Muller-Goyman CC. (2003). Solvent injection as a new approach for manufacturing lipid nanoparticles – evaluation of the method and process parameters. Eur J Pharm Biopharm 55:125–31.
Schwarz C, Mehnert W, Lucks JS, and Müller RH. (1994). Solid lipid nanoparticles (SLN) for controlled drug delivery-I. Production, characterization and sterilization. J Contr Rel 30(1): 83-96.
Schwarz C, and Mehnert W. (1997). Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm 157: 171-179.
Schwarz C. (1999). Solid lipid nanoparticles (SLN) for controlled drug delivery II. Drug incorporation and physicochemical characterization. J Microencapsul 16(2):205-213.
Shahgaldian P, Da Silva E, Coleman AW, et al. (2003). Para-acyl-calix-arene based solid lipid nanoparticles (SLNs): a detailed study of preparation and stability parameters. Int J Pharm 253:23–38.
Shahgaldian P, Gualbert J, Aïssa K, and Coleman AW. (2003). A study of the freeze-drying conditions of calixarene based solid lipid nanoparticles. Eur J Pharm Biopharm. 55(2):181-4.
Shamsunder D, Sandip C, Aruna K, and Krutika KS. (2013). Solid lipid nanoparticles and nanosuspension of adefovir dipivoxil for bioavailability improvement: formulation, characterization, pharmacokinetic and biodistribution studies. Drug Dev Ind Pharm 39 (5): 733-743.
Siekmann B, and Westesen K. (1992). Submicron-sized parenteral carrier systems based on solid lipids. Pharm Pharmacol Lett 1:123–6.
Siekmann B, Westesen K. (1994). Melt-homogenized solid lipid nanoparticles stabilized by the nonionic surfactant tyloxapol. I. Preparation and particle size determination, Pharm Phartel macol Lett 3: 194–197.
Siekmann B, and Westesen K. (1994). Thermoanalysis of the recrystallization of melt-homogenized glyceride nanoparticles. Colloids and surfaces B: Biointer 3: 159-175.
Sjostrom B, and Bergenstahl B. (1992). Preparation of submicron drug particles in lecithin-stabilized o/w emulsions I. Model studies of the precipitation of cholesterylacetate. Int J Pharm 88:53–62.
Smith A, and Hunneyball IM. (1986). Evaluation of poly (lactic acid) as a biodegradable drug delivery system for parenteral administration. Int J Pharm 30: 215-220.
Song C, and Liu S. (2005). A new healthy sunscreen system for human: Solid lipid nanoparticles as carrier for 3,4,5-trimethoxybenzoylchitin and the improvement by adding Vitamin E. Int J Biol Macromolecules 36:116–9.
Sumeet Sooda, Natarajan Jawahara, Kunal Jain, Kuppusamy Gowthamarajan, and Subramania Nainar Meyyanathan. (2013). Olanzapine Loaded Cationic Solid Lipid Nanoparticles for Improved Oral Bioavailability. Current Nanosci 9: 26-34.
Suresh G, Manjunath K, Venkateswarlu V, et al. (2007). Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles. AAPS Pharm Sci Tech 8:162-70.
Suvarna G, Narender D, and Kishan V. (2015). Preparation, Characterization and In vivo Evaluation of Rosuvastatin Calcium Loaded Solid Lipid Nanoparticles. Int J Pharm Sci Nanotech 8(1): 2779-2785.
Swetha E, and Narendar D. (2017). Influence of β-Cyclodextrin and Hydroxypropyl-β-Cyclodextrin on Enhancement of Solubility and Dissolution of Isradipine. Int J Pharm Sci Nanotech 10(3):3752-3757.
Tao Yang, Huan-Huan Sheng, Nian-Ping Feng, Hai Wei, et al. (2013). Preparation of andrographolide-loaded solid lipid nanoparticles and their in vitro and in vivo evaluations: characteristics, release, absorption, transports, pharmacokinetics, and antihyperlipidemic activity. J Pharm Sci 102:4414–4425.
Thirupathi G, Swetha E, and Narendar D. (2017). Role of isradipine loaded solid lipid nanoparticles in the pharmacodynamic effect of isradipine in rats. Drug res 67(03): 163-169.
Uner M, Wissing SA, Yener G, et al. (2005b). Investigation of skin moisturizing effect and skin penetration of ascorbyl palmitate entrapped in solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) incorporated into hydrogel. Pharmazie 60:751–5.
Üner, M., and Yener, G. (2007). Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives. Int J Nanomedicine. 2(3):289-300.
Unruh T, Bunjes H, Westesen K, and Koch MHJ. (1999). Observation of size dependent melting in lipid nanoparticles. J Phys Chem B 103: 10373–10377.
Usha Kiranmai G, Narendar D, and Veerabrahma K. (2015). Preparation, characterization and in vivo evaluation of felodipine solid lipid nanoparticles to improve the oral bioavailability. Int J Pharm Sci Nanotech 8 (4): 1-8.
Vandita Kakkar, Sukhjit Singh, Dinesh Singla, and Indu Pal Kaur. (2011). Exploring solid lipid nanoparticles to enhance the oral bioavailability of curcumin. Mol Nutr Food Res 55: 495–503.
Venkatanaidu Karri, Arun Butreddy, and Narender D. (2015). Fabrication of efavirenz freeze dried nanocrystals: formulation, physicochemical characterization, in vitro and ex vivo evaluation. Adv Sci Engineer Med. 7(5): 385-392.
Venkateswarlu V, and Manjunath K. (2004). Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Rel 95:627–38.
Vijaykumar Nekkanti, Vobalaboina Venkateshwarlu, and Raviraj Pillai. (2013). Preparation, characterization and in vivo evaluation of raloxifene hydrochloride solid lipid nanoparticles. Pharm nanotechnol 1(1): 68-77.
Vila A, Gill H, McCallion O, and Alonso MJ. (2004). Transport of PLA-PEG particles across the nasal mucosa: effect of particle size and PEG coating density. J Control Rel 98:231–44.
Vinay Kumar V, Chandrasekhar D, Ramakrishn S, Kishan VB, Madhusudan Rao Y, and Prakash VD. (2007). Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics. Int J Pharm 335:167-175.
Vinay Kumar V, Raghavendra C, Rojarani K, Laxminarayana A, Ramakrishna S, and Prakash V D. (2012). Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloids Surf B 95, 1–9.
Westesen K, and Bunjes H. (1995). Do nanoparticles prepared from lipids solid at room temperature always possess a solid lipid matrix? Int J Pharm 115: 129-131.
Wissing SA, Kayser O, and Muller RH. (2004). Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev 56:1257–72.
Wissing SA, and Muller RH. (2001). A novel sunscreen system based on tocopherol acetate incorporated into solid lipid nanoparticles. Int J Cosm Sci 23:233–43.
Wissing SA, and Muller RH. (2003). Cosmetic applications for solid lipid nanoparticles (SLN). Int J Pharm 254:65–8.
Xie s, Zhu L, Dong L, et al. (2011). preparation and evaluation of ofloxacin-loaded palmitic acid solid lipid nanoparticles. Int J Nanomed 6:547-55.
Yang S, Zhu J, Lu Y, et al. (1999b). Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751–57.
Yang S, Zhu J, Lu Y, et al. (1999b). Body distribution of camptothecin solid lipid nanoparticles after oral administration. Pharm Res 16:751–57.
Yang SC, Lu LF, Cai Y, et al. (1999a). Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Rel 59:299–307.
Yun-Jie Dang and Chun-Yan Zhu. (2013). Oral bioavailability of cantharidin-loaded solid lipid nanoparticles. Dang and Zhu Chinese Med 8:1.
Zara GP, Bargoni A, Cavalli R, et al. (2002). Pharmacokinetics and tissue distribution of idarubicin loaded solid lipid nanoparticles after duodenal administration to rats. J Pharm Sci 91:1324-33.
Zhang N, Ping Q, Huanga G, et al. (2006). Lectin-modified solid lipid nanoparticles as carriers for oral administration of insulin. Int J Pharm 327:153-9.
Zhang SH, Shen SC, Chen Z, and Yun JX. (2008). Preparation of solid lipid nanoparticles in co-flowing microchannels. Chemic Engineer J 144: 324–328.
Zimmermann E, and Muller RH. (2001). Electrolyte- and pH-stabilities of aqueous solid lipid nanoparticle (SLNTM) dispersions in artificial gastrointestinal media. Eur J Pharm Biopharm 52:203–10.
Zur Muhlen A, and Mehnert W. (1998). Drug release and release mechanisms of prednisolone loaded solid lipid nanoparticles. Pharmazie 53:552–5.
Zur Muhlen A, Schwarz C, and Mehnert W. (1998). Solid lipid nanoparticles (SLN) for controlled drug delivery – Drug release and release mechanism. Eur J Pharm Biopharm 45:149–55.

Most read articles by the same author(s)